Unilife, a manufacturer of injectable drug delivery systems, has won a contract from French drugmaker Sanofi to supply Unifill Finesse, a customized device from its Unifill platform of prefilled syringes, for use with the anti-thrombotic therapy enoxaparin sodium sold under brand names Lovenox and Clexane.
As part of the deal, Sanofi received exclusive use of right for Unifill Finesse to be used with anti-thrombotic drugs for the period of the contract.
In addition, Sanofi can still retain exclusivity, even after a four year ramp-up period after market entry, if it buys a minimum of 150 million units of the Unifill Finesse or other Unifill syringes annually.
Unilife, on the other hand, is free to supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics.
Pursuant to the terms of the contract, Unilife is eligible to receive up to $15 million from Sanofi in milestones based payments with $5 million of these payments expected in 2013.
Unilife can also earn future revenues from the sale of Unifill Finesse syringes.
This supply contract, which replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform, can extend up to 2024.
